Development and validation of animal variant classification guidelines to objectively evaluate genetic variant pathogenicity in domestic animals
- PMID: 39703406
- PMCID: PMC11656590
- DOI: 10.3389/fvets.2024.1497817
Development and validation of animal variant classification guidelines to objectively evaluate genetic variant pathogenicity in domestic animals
Abstract
Assessing the pathogenicity of a disease-associated genetic variant in animals accurately is vital, both on a population and individual scale. At the population level, breeding decisions based on invalid DNA tests can lead to the incorrect inclusion or exclusion of animals and compromise the long-term health of a population, and at the level of the individual animal, lead to incorrect treatment and even life-ending decisions. Criteria to determine pathogenicity are not standardized, i.e., no guidelines for animal variants are available. Here, we aimed to develop and validate guidelines to be used by the community for Mendelian disorders in domestic animals to classify variants in categories based on standardized criteria. These so-called animal variant classification guidelines (AVCG) were based on those developed for humans by The American College of Medical Genetics and Genomics (ACMG). In a direct comparison, 83% of the pathogenic variants were correctly classified with ACMG, while this increased to 92% with AVCG. We described methods to develop datasets for benchmarking the criteria and identified the most optimal in silico variant effect predictor tools. As the reproducibility was high, we classified 72 known disease-associated variants in cats and 40 other disease-associated variants in eight additional species.
Keywords: (clinical) genetic testing; across-species classification; genetic variant datasets; in silico variant effect predictor tools; interpretation; neutral; pathogenic; reproducibility.
Copyright © 2024 Boeykens, Abitbol, Anderson, Casselman, de Citres, Hayward, Häggström, Kittleson, Lepri, Ljungvall, Longeri, Lyons, Ohlsson, Peelman, Smets, Vezzosi, van Steenbeek and Broeckx.
Conflict of interest statement
HA is an employee of Wisdom Panel Mars Petcare Science & Diagnostics, a company that offers canine and feline DNA testing as a commercial service. CDdC is an employee of Antagene, a DNA testing and genetic analysis company for dogs, cats, horses, and wildlife. The following authors interact (= discuss genetic tests, variants that have or will be published, …) on a regular basis with commercial companies: BJGB (Van Haeringen laboratorium, Laboklin, Wisdom Panel Mars Petcare Science & Diagnostics, Antagene), MA (Antagene, Wisdom Panel Mars Petcare Science & Diagnostics, Felome, Genindexe), JJH (Embark), ML (Vetogene, Genefast), however, there are no fees involved. None of the authors have received speaking fees from commercial genetic testing companies. None of the authors have performed paid consultant services for commercial genetic testing companies.
Figures
References
-
- Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. (2015) 17:405–24. doi: 10.1038/gim.2015.30, PMID: - DOI - PMC - PubMed
-
- Amendola LM, Jarvik GP, Leo MC, McLaughlin HM, Akkari Y, Amaral MD, et al. Performance of ACMG-AMP variant-interpretation guidelines among nine Laboratories in the Clinical Sequencing Exploratory Research Consortium. Am J Hum Genet. (2016) 98:1067–76. doi: 10.1016/j.ajhg.2016.03.024, PMID: - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
